Evaluate Vantage Homepage
A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.
A surprise move into the Car-T space suggests the beleaguered Belgian biotech still has an eye on its rich benefactor.
Real-world data on Translarna look good, but with a failed confirmatory trial and a troubled history US approval is far from guaranteed.
Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.
Pivotal data will show whether KarXT can walk the risk-benefit tightrope.
June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.
With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
But a surprise adcom for omecamtiv mecarbil might put a spanner in the works.
Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.
The Japanese drug maker has four more conjugates coming behind Enhertu, and plans to keep future successes to itself.